Late health outcomes after dexrazoxane treatment: A report from the Children’s Oncology Group

Chow EJ, Aplenc R, Vrooman LM, Doody DR, Huang YV, Aggarwal S, Armenian SH, Baker KS, Bhatia S, Constine LS, Freyer DR, Kopp LM, Leisenring WM, Asselin BL, Schwartz CL, Lipshultz SE. Late health outcomes after dexrazoxane treatment: A report from the Children’s Oncology Group. Cancer. 2022 Feb 15;128(4):788-796. doi: 10.1002/cncr.33974. Epub 2021 Oct 13. PubMed PMID: 34644414; PubMed Central PMCID: PMC8792306.

Examine the long-term outcomes among children newly diagnosed with cancer treated on dexrazoxane-containing clinical trials. P9404 (acute lymphoblastic leukemia/lymphoma [ALL]), P9425 and P9426 (Hodgkin lymphoma), P9754 (osteosarcoma), and Dana-Farber Cancer Institute 95–01 (ALL) enrolled 1,308 patients between 1996–2001: 1,066 were randomized (1:1) to doxorubicin±dexrazoxane and 242 (from P9754) were non-randomly assigned to receive dexrazoxane. Trial data were linked with the National Death Index, the Organ Procurement and Transplantation Network, Pediatric Health Information Systems (PHIS), and Medicaid. Osteosarcoma survivors from the Childhood Cancer Survivor Study (CCSS; n=495, no dexrazoxane) served as a comparator in sub-analyses. Follow-up events were assessed using cumulative incidence, Cox regression, and Fine-Gray methods.